ImageneBio, Inc. (NASDAQ:IMA) Given Average Recommendation of “Hold” by Analysts

ImageneBio, Inc. (NASDAQ:IMA) has received a consensus recommendation of “Hold” from the five brokerages that are covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $29.00.

A number of research firms recently weighed in on IMA. Weiss Ratings reissued a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. HC Wainwright initiated coverage on shares of ImageneBio in a research note on Friday, August 21st. They issued a “buy” rating and a $28.00 price objective for the company. Wall Street Zen lowered ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. Finally, Wedbush restated an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th.

ImageneBio Stock Performance

Shares of IMA stock opened at $5.33 on Friday. The stock has a fifty day simple moving average of $5.77 and a two-hundred day simple moving average of $5.81. The firm has a market capitalization of $60.50 million, a PE ratio of -1.16 and a beta of 0.76. ImageneBio has a 52-week low of $3.94 and a 52-week high of $13.98.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.27. On average, sell-side analysts forecast that ImageneBio will post -3.23 EPS for the current fiscal year.

Institutional Trading of ImageneBio

Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its stake in shares of ImageneBio by 13.5% in the fourth quarter. Geode Capital Management LLC now owns 54,146 shares of the company’s stock worth $374,000 after buying an additional 6,458 shares during the last quarter. Barclays PLC grew its position in shares of ImageneBio by 170.8% in the fourth quarter. Barclays PLC now owns 10,797 shares of the company’s stock valued at $74,000 after purchasing an additional 6,810 shares during the period. Goldman Sachs Group Inc. acquired a new stake in ImageneBio in the 4th quarter worth about $76,000. Millennium Management LLC purchased a new stake in shares of ImageneBio during the fourth quarter worth approximately $79,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of ImageneBio during the third quarter worth $104,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.